Proton magnetic resonance spectroscopy measurements of glutamate and GABA are important in neuropsychiatric research. Some study designs require simultaneous measurement of both metabolites. GABA measurement requires specialized pulse sequences, the most common approach being J-difference spectral editing with MEGA-PRESS. This method enables two different strategies for concurrently measuring glutamatefrom either off-resonance or difference spectra. However, it is uncertain how either strategy compares to conventional glutamate measurements. Here we compared these approaches in 49 subjects (28 healthy volunteers and 21 first-episode psychosis patients), in whom both PRESS (TE 80) and MEGA-PRESS (TE 68) spectra were obtained from dorsolateral prefrontal cortex. Glutamate and glx estimates from MEGA-PRESS difference and offresonance spectra were compared to glutamate and glx estimates from PRESS spectra using correlational analyses. In healthy volunteers, correlations between PRESS and MEGA-PRESS off-resonance values were r ≥ 0.88 and were significantly higher than correlations between PRESS and MEGA-PRESS difference spectrum values (r ≤ 0.36). Patients showed a similar pattern. Lower correlations with difference spectrum values may reflect a disproportionate impact of field instabilities on co-edited glutamate signals. The results suggest that MEGA-PRESS off-resonance spectra can substitute for separately-acquired PRESS spectra in studies requiring simultaneous glutamate and GABA measurements.
Introduction 1
Proton magnetic resonance spectroscopy (1H-MRS) is a technique for the non-invasive measurement of neurometabolites in defined regions of the human brain. Using optimized acquisition sequences, 10 or more different brain metabolites may be present in sufficiently high concentration to be measurable with clinical scanners. Among these metabolites, glutamate and GABA are of particular interest, as their functions include serving as the principal excitatory and inhibitory neurotransmitters, respectively. Disruption of glutamatergic and GABAergic systems has been implicated in a variety of neuropsychiatric disorders, including psychotic disorders, seizure disorders, and mood disorders (Jun et al., 2014; Luykx et al., 2012; Maddock and Buonocore, 2012; Marsman et al., 2013; Schur et al., 2016; van Veenendaal et al., 2015) . Aspects of brain metabolism or neurotransmission involving glutamate and GABA may be promising targets for the development of novel treatments for these disorders (Poels et al., 2014; Waschkies et al., 2014) . Thus, 1H-MRS may have a key role in testing the engagement of targeted mechanisms by such novel treatments. While many clinical investigators may wish to measure glutamate and GABA simultaneously, it is not yet clear to what extent this can be adequately done using a single 1H-MRS acquisition sequence. Glutamate is most often measured using conventional PRESS or STEAM sequences, while measuring GABA on a clinical scanner requires use of a specialized acquisition sequence (Wijtenburg et al., 2015; Harris et al., 2017) , the most widely used of which is the MEGA-PRESS sequence (Mescher et al., 1998) . MEGA-PRESS sequences used to measure GABA can also provide nominal measures of glutamate (Mescher et al., 1998) 
